ClinicalTrials.gg
RecruitingNCT07387952Updated Feb 4, 2026

The Safety and Efficacy of Fecal Microbiota Transplantation Combined With Nutritional Intervention in the Treatment of Functional Constipation:a Pilot Study

An interventional study of FMT in Constipation - Functional, Fecal Microbiota Transplantation (FMT) and Chronic Constipation, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Constipation with a site in China — 35 open to participants now, 37 under way, 1 of them phase 3. Constipation · China.

Planned enrollment
93rd of 93
5 · median 100
Started
2025
with 14 others
No phase
56 of 109
21 open now
Primary completion
2026-12
later than 19 of 36 live
Registered
90th of 109
by date
Lead sponsor
4 of 109
Peking Union Medical College Hospital

Among the 109 studies in Constipation with a site in China, this one is the 93rd largest by planned enrollment of the 93 interventional ones that give a count, is one of 15 that started in 2025, is one of 56 with no phase, reaches primary completion later than 19 of the 36 other live ones, and was the 90th registered.

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

Browse Constipation studies →

Open to participants now

35 of the 109 studies in Constipation with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Constipation with a site in China, or all of them as a file.
02

Study summary

Chronic constipation is a common gastrointestinal disease with a global prevalence of about 15%, significantly affecting daily life and quality of life. Traditional treatments primarily rely on laxatives, which may lead to adverse effects with prolonged use, while surgical interventions have limited patient acceptance. Recent studies indicate that gut microbiota therapies-including probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT)-can effectively manage chronic constipation. This study aims to investigate the safety and efficacy of FMT combined with a prebiotic nutritional intervention (using a co-localization strategy) in the treatment of functional constipation. Additionally, the investigators will explore changes in fecal microbiota and metabolomic profiles following the treatment.

03

Conditions studied

  • Constipation - Functional
  • Fecal Microbiota Transplantation (FMT)
  • Chronic Constipation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 70.
  2. Diagnostic criteria: Functional constipation (FC) in accordance with Rome IV criteria, which should meet the following conditions:

    • Symptom requirements: The following at least 2 items should occur in ≥25% of bowel movements: a. Straining during defecation; b. Hard stool (Bristol Stool Classification score 1-2); c. Feeling of incomplete evacuation; d. Rectal obstruction sensation; e. Need for finger assistance during defecation; f. Spontaneous bowel movements \<3 times per week.
    • It is rare to have loose stools without laxatives.
    • Exclusion of irritable bowel syndrome (IBS): IBS diagnosis criteria not meeting Rome IV.
    • Disease course requirements: Symptoms persist for at least 6 months and meet the above criteria within the last 3 months.
  3. Traditional treatment methods (dietary intervention, at least two laxatives or probiotics) are ineffective.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation.
  2. Unable to take the intervention product or complete the examination as required.
  3. Language expression disorder or mental illness.
  4. Physical examination showed severe liver and kidney dysfunction.
  5. Acute gastrointestinal disease within 4 weeks.
  6. Constipation caused by surgery in the past 4 weeks.
  7. History or abnormal examination: cancer, severe enteritis, intestinal obstruction, inflammatory bowel disease, hypothyroidism, mental illness, stroke, heart disease, cirrhosis, renal failure, hematopoietic system diseases, organic bowel disease suggested by colonoscopy or imaging.
  8. Participation in other clinical trials within 3 months prior to enrollment.
  9. Other health problems are not suitable for participation in the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    FMT with nutritional intervention group

    Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota, by extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota. Nutritional intervention involves high dietary fiber preparation.

    Procedure: FMT

Interventions

  • ProcedureFMT

    In this group, colonoscopy is performed and a colostomy is placed in the ileocecal region. Bacterial infusion is performed for 3 days with 100ml graft per day. Within 30 minutes after receiving the microbiota transplantation, take the high dietary fiber preparation and dissolve it in water according to the instructions. Blood, stool, and colonoscopy-derived mucosal samples are collected before and after FMT and Researchers conduct follow-ups.

    Also known as: FMT with nutritional intervention

06

What researchers measure

Primary outcomes

  1. Frequency of Defecation (Spontaneous Bowel Movements)

    The number of Spontaneous Bowel Movements (SBM) per week recorded by the participant in a diary.

    Time frame: Baseline, Weeks 4, 8, 12, 18, and 24

  2. Stool Consistency Assessed by Bristol Stool Form Scale (BSFS)

    Stool consistency is evaluated using the Bristol Stool Form Scale. The scale ranges from Type 1 (Separate hard lumps) to Type 7 (Liquid consistency). Type 1 and 2 indicate constipation, while Type 3 and 4 are considered normal. Higher scores indicate looser stool consistency.

    Time frame: Baseline, Weeks 4, 8, 12, 18, and 24

  3. Severity of Defecation Straining

    Patient-reported assessment of the effort required to defecate. Participants rate their straining severity on a scale (e.g., from 0 to 3, where 0 represents no straining and 3 represents severe straining). Higher scores indicate worse symptoms.

    Time frame: Baseline, Weeks 4, 8, 12, 18, and 24

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Number of participants with adverse events. Assessment includes monitoring for specific gastrointestinal symptoms (e.g., aggravation of diarrhea, abdominal discomfort/bloating) and systemic infections (e.g., secondary intestinal infection, bacteremia). Safety is assessed via telephone and offline visits.

    Time frame: From baseline through Week 24

  2. Change in Gut Microbiota Composition Assessed by Metagenomic Sequencing

    Fecal samples are collected to analyze the changes in the gut microbiota structure. Analysis includes the relative abundance of bacterial species and diversity indices (e.g., Shannon index) using Metastats analysis to compare pre- and post-treatment compositions.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 18, and 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 246 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 17 months is close to that.

Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Feb 4, 2026
StartActual
Jul 30, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07387952
Responsible party
Sponsor
First posted
Feb 4, 2026
Start date
Jul 30, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 4, 2026

Study contacts

Pengguang Yan
Contact
pengchengf@mail.sdu.edu.cn
+8618810309887
Jingnan Li, MD, Ph.D
study chair · Peking Union Medical College Hospital, Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion